Aribio Wins Indonesian Approval for Four Next-Generation Hyaluronic Acid Fillers
Translated from Korean and summarized by DistantNews. Read the original for the full story.
At a glance
News
Named sources
Approved/passed
- Aribio and Aribio Lab said Indonesia’s Food and Drug Authority approved four products under their Bidan hyaluronic acid filler brand.
- The company said it developed the fillers over seven years and plans to enter Indonesia’s market.
Aribio and Aribio Lab are moving to target Indonesia’s 300 million-person market with four hyaluronic acid fillers developed by the companies themselves.
The products, sold under the Bidan brand, received item approval from Indonesia’s Food and Drug Authority, known as BPOM, the companies said on Sept. 8.
Bidan is a hyaluronic acid filler line that the Aribio group developed over seven years. The source also identifies the company’s proprietary technology as PCRT, although the supplied text ends before the technology’s full description.
About this summary
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.
More Stories
“It’s Physical Condition, Not Age”: First Domestic Evidence Shows Benefits of Transplants for Older …
Dementia Patients Ask for Help Managing Their Assets as Applications Surge 30-Fold in Three Months
Even with unpaid phone bills, callers will be connected to suicide prevention line 109 from October
From Our Blog
News in Translation: What Gets Lost, and How We Keep the Framing
Diaspora Media: How Communities Follow News From Home
Traveling Where the Press Is Not Free: How to Read the News There
The Digital Nomad's Guide to Local News
The Same Story, Different Countries: How Coverage Changes at the Border
